MarketBeat
13 Jun 2026, 18:07 UTC · 3h ago
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
13 Jun 2026, 18:07 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
The Phase 3 RISE UP trial of mitapivat in sickle cell disease failed to achieve statistical significance on its primary endpoint of annualized rate of pain crisis and a key secondary endpoint for fatigue. — Missing a primary endpoint in a pivotal Phase 3 trial typically creates significant regulatory hurdles and reduces the projected commercial peak for the drug.
-0.60Agios is initiating REIGNITE, a confirmatory Phase 3 trial for sickle cell disease under the U.S. Accelerated Approval Pathway, focusing on transfusion independence. — The move toward an Accelerated Approval Pathway provides a viable regulatory bridge despite the RISE UP pain crisis miss.
+0.40Long-term extension data from the Phase 3 ENERGIZE trial showed that the mean duration of hemoglobin response for mitapivat in thalassemia patients more than doubled from 17.9 to 43.6 weeks. — Demonstrated durability of response strengthens the long-term value proposition and competitive positioning of AQVESME.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Agios is transitioning from a single-asset company to a multi-asset platform, adding programs in polycythemia vera, immune thrombocytopenia, and phenylketonuria. — Diversifying the pipeline reduces binary risk associated with a single drug's success or failure.
+0.20As of March 31, AQVESME had 242 prescriptions written by REMS-certified physicians. — Provides an early, albeit small, quantitative benchmark for commercial adoption.
+0.10Which stocks this story touches
The company reported positive long-term thalassemia data and strong hemoglobin response in sickle cell disease, despite missing a pain endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
6h ago
